A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP

Immune Thrombocytopenia Clinical Trial

Official title:

High-dose Dexamethasone Plus Diammonium Glycyrrhizinate Enteric-coated Capsule Versus High-dose Dexamethasone in Treatment-naive Primary Immune Thrombocytopenia (ITP): a Multicentre, Randomised, Open-label Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05023915
• Other study ID #: ITP-Diammonium Glycyrrhizinate
• Status: Recruiting
• Phase: Phase 2
• Start date: August 21, 2021
• Est. completion date: July 31, 2022

Study information

• Verified date: August 2021
• Source: Shandong University
• Contact: Ming Hou, MD,PhD
• Phone: +86-531-82169879
• Email: qlhouming[@]sina.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsule plus high-dose dexamethasone for the treatment of adults with newly-diagnosed primary immune thrombocytopenia (ITP).

Description:

The investigators anticipate to undertaking a parallel group, randomised controlled trial of 106 ITP patients. One part of the participants are randomly selected to receive diammonium glycyrrhizinate enteric-coated capsule orally at a dose of 150mg tid for 3 months), combining with dexamethasone (given orally at a dose of 40 mg qd for 4 days). The others are selected to receive high-dose of dexamethasone alone. Patients who do not respond to the treatment may receive another cycle of high-dose dexamethasone therapy with an interval of 10 days. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study. The purpose of this study is to report the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsule combining with high-dose dexamethasone therapy for the treatment of ITP.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 106
• Est. completion date: July 31, 2022
• Est. primary completion date: August 21, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Meet the diagnostic criteria for immune thrombocytopenia;

• Untreated hospitalized patients or patients from the clinic, may be male or female, between the ages of 18~ 80 years;

• To show a platelet count <30 * 10^9/L, or with bleeding manifestations, or both;

• Willing and able to sign written informed consent

• ITP patients with hepatitis virus infection or ITP patients with abnormal liver function at the time of enrollment, i.e., ITP patients with indications for diammonium glycyrrhizinate enteric-coated capsule, should be separately stratified.

Exclusion Criteria:

• secondary thrombocytopenia;

• severe immune-deficiency;

• active or previous malignancy;

• HIV virus infection, tuberculosis, or other active infection (sepsis, pneumonia, or abscess);

• pregnancy or lactation;

• diabetes;

• hypertension;

• cardiovascular diseases;

• severe kidney function impairment;

• psychosis;

• osteoporosis;

• inflammatory bowel disease or gastric disease;

• arterial or venous thromboembolism within the 6 months before screening or patients who required anticoagulant treatment;

• an organ or haematopoietic stem-cell transplantation;

• neutrophil count of less than 1500 cells per mm³;

• glycosylated haemoglobin less than 8%;

• partial thromboplastin time 1·5 times or less the upper limit of normal (ULN); •clinical electrocardiogram changes;

• history of primary immunodeficiency;

• neoplastic disease within the past 5 years;

• corrected QT interval greater than 450 ms for men and greater than 470 ms for women;

• substance misuse within the previous 12 months;

• people who could not adhere to the protocol or were planning to have a surgical procedure in 6 months.

Related Conditions & MeSH terms

• Immune Thrombocytopenia
• Purpura, Thrombocytopenic, Idiopathic
• Thrombocytopenia

Intervention

Drug:
• dexamethasone
40 mg qd for 4 days
• diammonium glycyrrhizinate enteric-coated capsule
150mg tid for 3 months

Locations

Country	Name	City	State
China	Qilu hospital, Shandong University	Jinan	Shandong
China	Qilu hospital (Qingdao), Shandong University	Qingdao	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Shandong University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	14-day initial overall response to ITP treatments	Complete response was defined as a platelet count of 100×10? cells per L or higher and an absence of bleeding. Partial response was defined as a platelet count of 30×10? cells per L or higher, but less than 100×10? cells per L, and at least a doubling of the baseline platelet count and an absence of bleeding. Platelet counts were confirmed on two separate occasions at least 7 days apart when defining complete response or partial response. No response was defined as a platelet count of less than 30×10? cells per L, or less than two-times increase from baseline platelet count, or bleeding.	14 days after treatment started
Primary	6-month sustained overall response to ITP treatments	Complete response was defined as a platelet count of 100×10? cells per L or higher and an absence of bleeding. Partial response was defined as a platelet count of 30×10? cells per L or higher, but less than 100×10? cells per L, and at least a doubling of the baseline platelet count and an absence of bleeding. Platelet counts were confirmed on two separate occasions at least 7 days apart when defining complete response or partial response. No response was defined as a platelet count of less than 30×10? cells per L, or less than two-times increase from baseline platelet count, or bleeding.	A response lasting for at least 6 months without any additional intervention specific to primary immune thrombocytopenia was defined as a sustained response
Secondary	time to response	the time from treatment initiation to achieve a complete response or a partial response	an average of 6 months
Secondary	duration of response	the time from achievement of a complete response or a partial response to the loss of response (platelet count <30×10? cells per L; measured on two occasions more than 1 day apart or the presence of bleeding).	through study completion, an average of one year
Secondary	therapy associated adverse events	nausea and diarrhea (report in frequency); pruritus (report in frequency); headache and dizziness (report in frequency)	up to one year